Orexigen Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 7, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows:
The 15th Annual BIO CEO & Investor Conference |
|
Date: |
Tuesday, February 12, 2013 |
Time: |
2:00 p.m. Eastern Time |
Location: |
The Waldorf Astoria, New York |
2013 Leerink Swann Global Healthcare Conference |
|
Date: |
Wednesday, February 13, 2013 |
Time: |
11:30 a.m. Eastern Time |
Location: |
The Waldorf Astoria, New York |
The BIO CEO & Investor Conference presentation will be webcast live. To access the webcast, please visit the Investor Relations section of the company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.
Orexigen Contact:
McDavid Stilwell
VP, Corporate Communications and Business Development
(858) 875-8629
Media Contact:
Denise Powell
BrewLife
(510) 703-9491
SOURCE Orexigen Therapeutics, Inc.
Share this article